What foods should I eat for Stomach / Gastric Cancer (Nutritional Support)?

Small, frequent meals (6–8/day) — essential for dumping syndrome management post-gastrectomy; reduces rapid gastric emptying; most important dietary strategy after gastrectomy. High-quality protein (eggs, chicken, fish, Greek yogurt, cottage cheese) — 1.5–2g/kg/day; counteract cachexia; support wound healing post-gastrectomy; small portions at each meal. Cooked vegetables (carrots, zucchini, sweet potatoes, spinach) — antioxidants; easy to digest; anti-tumor; avoid raw vegetables initially post-gastrectomy

What supplements help with Stomach / Gastric Cancer (Nutritional Support)?

Vitamin B12 (methylcobalamin) — 1,000mcg IM injection monthly OR 1,000–2,000mcg oral daily (high-dose oral partially absorbed by passive diffusion); MANDATORY after total gastrectomy; intrinsic factor loss causes pernicious anemia; lifelong supplementation required. Iron (ferrous bisglycinate) — 25–50mg elemental iron daily with vitamin C; universal after gastrectomy; reduced gastric acid impairs iron absorption; ferrous bisglycinate is best tolerated; IV iron (ferric carboxymaltose) if oral is insufficient. Calcium citrate — 1,200–1,500mg daily in divided doses; calcium citrate does not require gastric acid for absorption (unlike calcium carbonate); essential post-gastrectomy; take with vitamin D3

What are the key nutrients for Stomach / Gastric Cancer (Nutritional Support)?

Key nutrients for Stomach / Gastric Cancer (Nutritional Support) include: Vitamin B12, Iron, Calcium citrate, Vitamin D3, Omega-3, Vitamin C, Glutamine, Probiotics, Curcumin, Zinc.

All Conditions

Cancer & Oncology Support

Stomach / Gastric Cancer (Nutritional Support)

H. pylori-driven adenocarcinoma with transformative HER2-targeted and immunotherapy combinations requiring aggressive nutritional support for post-gastrectomy malabsorption and cachexia

Vitamin B12IronCalcium citrateVitamin D3Omega-3Vitamin CGlutamineProbioticsCurcuminZinc

Overview

Gastric cancer is the fifth most common cancer globally (~1.09 million new cases/year) and the fourth leading cause of cancer death. Adenocarcinoma accounts for >95% of gastric cancers. Two main subtypes: intestinal type (associated with H. pylori, dietary factors, atrophic gastritis — declining in Western countries) and diffuse type (signet ring cell, linitis plastica — more aggressive, younger patients, hereditary diffuse gastric cancer — CDH1 mutations). H. pylori infection is the primary risk factor (~89% of non-cardia gastric cancers). Five-year survival: ~70% (stage I), ~32% (stage II), ~18% (stage III), ~5% (stage IV). Treatments: gastrectomy (total or subtotal with D2 lymphadenectomy), perioperative chemotherapy (FLOT: docetaxel + oxaliplatin + leucovorin + 5-FU — FLOT4 trial: improved OS from 35 to 50 months vs ECF/ECX), adjuvant chemoradiation (INT-0116), trastuzumab + chemotherapy (HER2+ gastric cancer — ToGA trial: 13.8 vs 11.1-month OS), ramucirumab (anti-VEGFR2 — REGARD/RAINBOW trials), pembrolizumab + chemotherapy (KEYNOTE-590/811 — first-line for PD-L1 CPS ≥1 and HER2+ gastric cancer), nivolumab + chemotherapy (CheckMate 649 — first-line for CPS ≥5). 2025–2026 advances: zolbetuximab (Vyloy — anti-CLDN18.2, FDA approved March 2024 for CLDN18.2+/HER2- gastric cancer — SPOTLIGHT: PFS 10.6 vs 8.7 months; OS 18.2 vs 15.5 months); fam-trastuzumab deruxtecan (T-DXd/Enhertu — DESTINY-Gastric01: 51% ORR in HER2+ gastric cancer, FDA approved 2021; DESTINY-Gastric04 2025: T-DXd vs ramucirumab + paclitaxel second-line — results pending); nivolumab adjuvant (CheckMate 577 for resected esophagogastric junction cancer — DFS benefit confirmed); pembrolizumab + trastuzumab + chemotherapy first-line for HER2+ (KEYNOTE-811 final OS 2024: 20.0 vs 16.8 months); CLDN18.2 CAR-T (CT041) in Phase II showing 57% ORR; ivonescimab (anti-PD-1 + anti-VEGF bispecific) in Phase III for gastric cancer; margetuximab (Fc-optimized anti-HER2) + chemotherapy for HER2+ gastric cancer; comprehensive biomarker testing (HER2, PD-L1 CPS, CLDN18.2, MSI, TMB, FGFR2) now standard for all advanced gastric cancers. Nutritional rationale: post-gastrectomy malabsorption is the most critical nutritional challenge — total gastrectomy causes vitamin B12 deficiency (intrinsic factor loss), iron deficiency, calcium malabsorption, dumping syndrome, and fat malabsorption; cachexia affects 60–80% of gastric cancer patients; H. pylori eradication and dietary modification reduce recurrence risk.

Evidence highlight: Zolbetuximab (Vyloy) FDA approved March 2024 for CLDN18.2+/HER2- gastric cancer — SPOTLIGHT: PFS 10.6 vs 8.7 months, OS 18.2 vs 15.5 months (Shah et al., 2023). KEYNOTE-811 final OS (2024): pembrolizumab + trastuzumab + chemo 20.0 vs 16.8 months for HER2+ gastric cancer. T-DXd FDA approved 2021 — DESTINY-Gastric01: 51% ORR vs 14% (Shitara et al., 2020). CLDN18.2 CAR-T (CT041): 57% ORR in Phase II (Qi et al., 2022). FLOT4: perioperative FLOT improved OS 35 to 50 months vs ECF/ECX (Al-Batran et al., 2019). CheckMate 649: nivolumab + chemo OS 14.4 vs 11.1 months for CPS ≥5 (Janjigian et al., 2021). H. pylori eradication reduces gastric cancer risk by 50% (Ford et al., 2020 Cochrane review).

Core Nutrition Principles

1Post-gastrectomy vitamin B12 deficiency is inevitable after total gastrectomy — intrinsic factor is produced in the stomach; lifelong B12 supplementation (IM injection or high-dose oral) is mandatory
2Dumping syndrome (early and late) is the most common post-gastrectomy complication — small frequent meals, avoiding liquids with meals, low-simple-sugar diet, and lying down after meals reduce symptoms
3Iron deficiency anemia is universal after gastrectomy — gastric acid is required for iron absorption; iron supplementation with vitamin C is essential; IV iron may be needed
4Calcium malabsorption occurs after gastrectomy — reduced gastric acid impairs calcium absorption; calcium citrate (not carbonate) is preferred; vitamin D3 essential
5Cachexia affects 60–80% of gastric cancer patients — high protein intake (1.5–2g/kg/day), calorie-dense foods, and oral nutritional supplements are essential for weight maintenance
6H. pylori eradication reduces gastric cancer recurrence risk by 50% — triple or quadruple antibiotic therapy; probiotic support during and after eradication therapy
7Salt-preserved and smoked foods are the strongest dietary risk factors for gastric cancer — nitrosamines and salt damage gastric mucosa; Mediterranean diet reduces risk by 30–40%
8Antioxidants (vitamin C, beta-carotene, selenium) reduce gastric cancer risk by protecting against H. pylori-induced oxidative damage and nitrosamine formation

Priority Foods

Small, frequent meals (6–8/day) — essential for dumping syndrome management post-gastrectomy; reduces rapid gastric emptying; most important dietary strategy after gastrectomy
High-quality protein (eggs, chicken, fish, Greek yogurt, cottage cheese) — 1.5–2g/kg/day; counteract cachexia; support wound healing post-gastrectomy; small portions at each meal
Cooked vegetables (carrots, zucchini, sweet potatoes, spinach) — antioxidants; easy to digest; anti-tumor; avoid raw vegetables initially post-gastrectomy
Citrus fruits and bell peppers — vitamin C; reduce nitrosamine formation; antioxidant; enhance iron absorption from plant foods
Wild-caught fatty fish (salmon, sardines, mackerel) — omega-3 EPA/DHA; anti-inflammatory; anti-tumor; anti-cachexia; easy to digest
Garlic and onions — allicin; H. pylori inhibition; anti-tumor; associated with reduced gastric cancer risk in prospective studies
Green tea (3–5 cups/day) — EGCG; anti-tumor in gastric cancer cell lines; H. pylori inhibition; antioxidant; associated with reduced gastric cancer risk in Asian populations
Fermented foods (kefir, yogurt — after H. pylori eradication) — Lactobacillus; gut microbiome restoration; H. pylori suppression; immune support
Avocado and olive oil — calorie-dense; healthy fats; anti-inflammatory; critical for weight maintenance; tolerated well post-gastrectomy
Bone broth — collagen, glycine; gut mucosal healing; easy to consume; electrolytes; protein
Turmeric with black pepper — curcumin; anti-tumor in gastric cancer cell lines; H. pylori inhibition; NF-kB inhibition; anti-inflammatory

Core Supplements

Vitamin B12 (methylcobalamin) — 1,000mcg IM injection monthly OR 1,000–2,000mcg oral daily (high-dose oral partially absorbed by passive diffusion); MANDATORY after total gastrectomy; intrinsic factor loss causes pernicious anemia; lifelong supplementation required
Iron (ferrous bisglycinate) — 25–50mg elemental iron daily with vitamin C; universal after gastrectomy; reduced gastric acid impairs iron absorption; ferrous bisglycinate is best tolerated; IV iron (ferric carboxymaltose) if oral is insufficient
Calcium citrate — 1,200–1,500mg daily in divided doses; calcium citrate does not require gastric acid for absorption (unlike calcium carbonate); essential post-gastrectomy; take with vitamin D3
Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); fat malabsorption and reduced sun exposure cause deficiency; immune support; anti-tumor; target 60–80 ng/mL
Omega-3 EPA/DHA — 3–4g daily; anti-cachexia; anti-inflammatory; anti-tumor; reduce prostaglandin E2; preserve lean mass
Vitamin C — 1,000–2,000mg daily; reduces nitrosamine formation; antioxidant; enhances iron absorption; immune support; H. pylori inhibition
Zinc picolinate — 30mg daily; wound healing post-gastrectomy; immune function; taste recovery; antioxidant; gastric acid required for zinc absorption — monitor levels
Probiotics (50 billion CFU multi-strain) — gut microbiome restoration after H. pylori eradication and antibiotics; reduce H. pylori recurrence; Lactobacillus rhamnosus GG + Bifidobacterium longum
Glutamine — 10–20g daily; gut mucosal integrity post-gastrectomy; reduces chemotherapy-induced mucositis; muscle preservation; anti-cachexia
Magnesium glycinate — 400–600mg daily; oxaliplatin (in FLOT) causes hypomagnesemia; muscle function; sleep; blood sugar regulation
Curcumin (phytosome) — 500–1,000mg twice daily; anti-tumor in gastric cancer cell lines; H. pylori inhibition; NF-kB inhibition; anti-inflammatory
Whey protein isolate — 30–40g daily; leucine-rich; anti-cachexia; muscle preservation; mix into smoothies; easy to consume post-gastrectomy

Treatment Protocols

H. pylori eradication — triple therapy (clarithromycin + amoxicillin + PPI x14 days) or quadruple therapy (bismuth + metronidazole + tetracycline + PPI x14 days); reduces gastric cancer recurrence risk by 50%; confirm eradication with urea breath test 4 weeks after treatment
Total or subtotal gastrectomy with D2 lymphadenectomy — standard curative surgery; D2 dissection (removal of perigastric and celiac lymph nodes) is standard in Asia and increasingly in the West
FLOT perioperative chemotherapy (FLOT4 trial) — docetaxel + oxaliplatin + leucovorin + 5-FU; 4 cycles pre-op + 4 cycles post-op; improved median OS from 35 to 50 months vs ECF/ECX; current standard in the West
Trastuzumab + chemotherapy (ToGA trial) — for HER2+ gastric cancer (~15–20%); trastuzumab + cisplatin/capecitabine or 5-FU; improved OS from 11.1 to 13.8 months; HER2 testing mandatory for all gastric cancers
Fam-trastuzumab deruxtecan (T-DXd, Enhertu) — ADC for HER2+ gastric cancer; DESTINY-Gastric01: 51% ORR vs 14% with chemotherapy; FDA approved 2021; second-line standard for HER2+ gastric cancer
Zolbetuximab (Vyloy) — anti-CLDN18.2 monoclonal antibody; FDA approved March 2024 for CLDN18.2+/HER2- gastric cancer; SPOTLIGHT trial: improved PFS (10.6 vs 8.7 months) and OS (18.2 vs 15.5 months); CLDN18.2 testing required
Nivolumab + chemotherapy (CheckMate 649) — first-line for CPS ≥5 gastric cancer; improved OS (14.4 vs 11.1 months); FDA approved 2021
Pembrolizumab + trastuzumab + chemotherapy (KEYNOTE-811) — for HER2+ gastric cancer; improved ORR (74% vs 52%); FDA approved 2021
Ramucirumab (Cyramza) — anti-VEGFR2; FDA approved for second-line gastric cancer; REGARD: improved OS (5.2 vs 3.8 months) as monotherapy; RAINBOW: improved OS (9.6 vs 7.4 months) with paclitaxel
Adjuvant chemoradiation (INT-0116) — for resected gastric cancer; 5-FU + leucovorin + 45 Gy radiation; improved OS from 27 to 36 months; used in US when perioperative chemotherapy not given
Post-gastrectomy nutritional rehabilitation — dietitian consultation essential; dumping syndrome management; B12/iron/calcium monitoring; oral nutritional supplements; jejunal feeding tube if oral intake insufficient
Dumping syndrome management — small frequent meals (6–8/day); avoid liquids with meals (drink 30–60 minutes after); avoid simple sugars; lie down 20–30 minutes after meals; pectin fiber slows gastric emptying
KEYNOTE-811 final OS (2024) — pembrolizumab + trastuzumab + chemotherapy: 20.0 vs 16.8 months OS for HER2+ gastric cancer; FDA approved 2021; now standard first-line for HER2+ disease
CLDN18.2 CAR-T (CT041) — Phase II showing 57% ORR in CLDN18.2+ gastric cancer; CLDN18.2 expressed in ~40% of gastric cancers; investigational; most promising CAR-T target in GI cancers
Ivonescimab — anti-PD-1 + anti-VEGF bispecific antibody; Phase III for gastric cancer (HARMONi-3); combines immunotherapy and anti-angiogenic mechanisms in single molecule; investigational
Comprehensive biomarker testing — HER2 (IHC/FISH), PD-L1 CPS, CLDN18.2 (IHC), MSI/MMR, TMB, FGFR2 amplification; all required for advanced gastric cancer to guide targeted therapy selection
Endoscopic surveillance — for patients with atrophic gastritis, intestinal metaplasia, or H. pylori history; upper endoscopy every 1–3 years based on risk

Foods & Substances to Avoid

Salt-preserved and smoked foods (salted fish, pickled vegetables, smoked meats, cured meats) — nitrosamines and salt damage gastric mucosa; strongest dietary risk factors for gastric cancer; avoid completely
Simple sugars and high-glycemic foods post-gastrectomy — trigger dumping syndrome (rapid gastric emptying causing hypoglycemia, sweating, palpitations); avoid candy, sugary drinks, white bread, and refined carbohydrates
Liquids with meals post-gastrectomy — accelerate gastric emptying and worsen dumping syndrome; drink 30–60 minutes before or after meals, not during
Alcohol — associated with increased gastric cancer risk; worsens gastric mucosa damage; interacts with chemotherapy; impairs H. pylori eradication; complete avoidance recommended
Processed meats (bacon, hot dogs, deli meats) — nitrosamines; associated with increased gastric cancer risk; WHO Group 1 carcinogen
Grapefruit with docetaxel, oxaliplatin, or ramucirumab — CYP3A4 inhibition alters drug levels
NSAIDs (ibuprofen, naproxen) — worsen gastric mucosa damage; interact with oxaliplatin; use acetaminophen for pain
Calcium carbonate supplements post-gastrectomy — requires gastric acid for absorption; use calcium citrate instead
Large meals post-gastrectomy — trigger dumping syndrome; switch to 6–8 small meals/day
Very hot foods and beverages — associated with increased gastric cancer risk (IARC Group 2A carcinogen); allow foods to cool before eating
Tobacco smoking — associated with increased gastric cancer risk; worsens H. pylori-induced gastric damage; impairs wound healing post-gastrectomy

Get your personalized protocol

Take the full assessment to receive a protocol tailored to your specific symptoms and goals.

Start Assessment

Key Nutrients

Vitamin B12IronCalcium citrateVitamin D3Omega-3Vitamin CGlutamineProbioticsCurcuminZinc

Drug & Supplement Interactions

Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.

Vitamin KSignificant

•Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
•Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
•Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2

Vitamin K2Significant

•Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
•Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR

Vitamin AModerate

•Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
•Warfarin — high-dose vitamin A may increase anticoagulant effect
•Orlistat — reduces fat-soluble vitamin absorption including vitamin A
•Cholestyramine — reduces vitamin A absorption

Vitamin B6Moderate

•Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
•Phenytoin and phenobarbital — B6 may reduce drug levels

Vitamin B3Moderate

•Statins — combination increases risk of myopathy; use with caution
•Diabetes medications — high-dose niacin may impair glucose control
•Blood pressure medications — additive vasodilatory effect

Vitamin DCaution

•Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
•Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
•Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
•Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
•Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
•Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses

Vitamin ECaution

•Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
•Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
•Statins — may reduce statin effectiveness at very high doses
•Cyclosporine — may reduce drug levels
•Niacin — high-dose combination may reduce HDL-raising effect of niacin

Vitamin CCaution

•Warfarin — high doses (>1g/day) may reduce anticoagulant effect
•Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
•Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
•Statins — very high doses may reduce statin effectiveness
•Aluminum antacids — vitamin C increases aluminum absorption; avoid combination

B12Caution

•Metformin — long-term use depletes B12; supplementation is recommended
•PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
•Chloramphenicol (antibiotic) — may reduce B12 effectiveness
•Colchicine (gout medication) — reduces B12 absorption

Vitamin B12Caution

•Metformin — long-term use depletes B12; supplementation is recommended
•PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
•Chloramphenicol — may reduce B12 effectiveness

IronCaution

•Antibiotics (tetracyclines, fluoroquinolones) — iron reduces drug absorption; separate by 2–4 hours
•Levothyroxine — iron reduces thyroid medication absorption; separate by 4+ hours
•Antacids and PPIs — reduce iron absorption; separate by 2+ hours
•Calcium supplements — compete for absorption; separate by 2+ hours
•Zinc — compete for absorption; separate by 2+ hours
•Vitamin C — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)

CalciumCaution

•Thyroid medications (levothyroxine) — calcium reduces absorption; separate by 4+ hours
•Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
•Bisphosphonates — reduces absorption; separate by 2+ hours
•Iron supplements — compete for absorption; separate by 2+ hours
•Digoxin — high calcium may increase risk of digoxin toxicity
•Thiazide diuretics — may cause hypercalcemia when combined with calcium supplements

Omega-3Caution

•Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
•Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
•Cyclosporine — may reduce drug levels; monitor in transplant patients

GlutamineCaution

•Lactulose (for hepatic encephalopathy) — glutamine may worsen ammonia levels in liver disease
•Anticonvulsants — glutamine may lower seizure threshold in some individuals
•Chemotherapy — may interfere with some agents; consult oncologist

ProbioticsCaution

•Immunosuppressants — use with caution; risk of infection in severely immunocompromised patients
•Antibiotics — take probiotics 2+ hours away from antibiotics to preserve viability
•Antifungals — may reduce probiotic viability

CurcuminCaution

•Blood thinners (warfarin, aspirin, clopidogrel) — additive antiplatelet effect at high doses
•Diabetes medications — may enhance blood-glucose-lowering effect
•Chemotherapy drugs — may interact with certain agents; consult oncologist
•Acid-reducing medications (PPIs, H2 blockers) — curcumin may reduce stomach acid
•Iron — may reduce iron absorption

ZincCaution

•Antibiotics (tetracyclines, fluoroquinolones) — zinc reduces antibiotic absorption; separate by 2+ hours
•Copper — high-dose zinc (>40mg/day) depletes copper; supplement 1–2mg copper per 30mg zinc
•Iron supplements — compete for absorption; separate by 2+ hours
•Penicillamine (for rheumatoid arthritis) — zinc reduces drug absorption
•Thiazide diuretics — increase zinc excretion

Zinc CarnosineCaution

•Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
•Copper — high-dose zinc depletes copper

This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.